目的 探讨胰岛素样生长因子2 mRNA结合蛋白3（IGF2BP3）限制性细胞毒性T淋巴细胞（CTL）表位诱导的CTL对肺癌细胞的作用。 方法 使用软件NetCTL 1.2、SYFPEITHI和IEDB预测选取IGF2BP3的人类白细胞抗原A2(HLA-A2)限制性表位肽。T2A2与表位肽的亲和力实验检测候选表位与T2A2细胞表面HLA-A2分子的结合能力，酶联免疫斑点（ELISPOT）实验检测候选表位肽诱导CTL分泌γ干扰素（IFN-γ）的能力，羧基荧光素二醋酸盐琥珀酰亚胺酯（CFSE）荧光染色检测细胞诱导CTL的能力。 结果 P143、P199、P280、P409、P515具有较好的结合力。表位肽P409、P515诱导的CTL具有较好的分泌IFN-γ的能力，并且对靶细胞具有一定的杀伤作用。  结论 P409、P515有望用于肿瘤的过继免疫治疗，可以成为抗肿瘤多肽免疫治疗疫苗的候选表位。

Objective Cancer immunotherapy is attractive for antigen-specific T cell-mediated antitumor therapy, especially in induction of cytotoxic T lymphocytes(CTL). In this report, we evaluated insulin-like growth factor 2 mRNA-binding protein 3(IGF2P3) restricted epitope-induced cytotoxic T lymphocytes effects in human lung cancer cells.   Methods The human leukocyte antigen A2(HLA-A2) restricted epitope peptides of IGF2P3 were selected by NetCTL 1.2, SYFPEITHI and IEDB software prediction. The binding affinity of the peptides to HLA-A02 molecules was evaluated by T2A2 cells binding assay. enzyme-linked immunosport(ELISPOT) assay was used to investigate the ability of the peptide to induce specific restricted cytotoxic T lymphocytes (CTL) and release of interferon γ(IFN-γ). The ability of the peptides to induce T cell response was investigated by carboxyfluorescein succinimidyl amino ester(CFSE) fluorescent staining.   Results The candidate peptide P143, P199, P280, P409 and P515 showed moderate affinity toward HLA-A2 molecule. ELISPOT assay showed P409, P515 were able to induce specific CTL and higher levels of IFN-γ were released. The CTL induced by P409, P515 lysed target cells.  Conclusion P409 and P515 have the potential for adoptive immunotherapy and can be used as candidate epitopes for new anti-tumor polypeptide immunotherapy vaccine. P409 and P515 can be used in peptide-based immunotherapy for lung cancer.